This manual focuses on how and when a set of low-cost or free drugs should be used in developing countries to control a set of diseases caused by worm infections. Preventive chemotherapy in this context means using drugs that are effective against a broad range of worm infections to simultaneously treat the four most common diseases caused by worms: river blindness (onchocerciasis), elephantiasis (lymphatic filariasis), schistosomiasis, and soil-transmitted helminthiasis. Significant opportunities also exist to integrate these efforts with the prevention and control of diseases such as trachoma. The new approach provides a critical first step in combining treatment regimens for diseases which, although different in themselves, require common resources and delivery strategies for control or elimination.

Based on papers presented at the XI International Congress for Tropical Medicine and Malaria, this publication provides an authoritative evaluation of treatment and control of helminth parasite infections. A section on leprosy and a brief review of malaria vaccination are included. A comprehensive review of the history of schistosomiasis control programs presents information unavailable elsewhere. This book is of special interest to professionals concerned with health problems of less developed countries and in particular to public health officials, epidemiologists and clinicians dealing with patients in or returning from the tropics.

Control of parasitic infections of humans has progressed rapidly over the last three decades. Such advances have resulted from focal disease control efforts based on historically effective interventions to new approaches to control following intensive research and pilot programs. Control of Human Parasitic Diseases focuses on the present state of control of the significant human parasitic infectious diseases. Includes the impact of recent research findings on control strategy Discusses the health policy implications of these findings and the importance of evaluation and monitoring Highlights the lessons learned and the interactions between control programs and health systems Foreword by Jeffrey D. Sachs

"Have a chew of dulie," said Crubog . . . "What is it?" asked Potter, half-suspiciously. "Seaweed. " "Is it good for the virility? . . . " "And what is the virility?" asked the old man. "Does it make you more attractive to women?" Potier shouted in his ear. "No. " "What is it good for then?" "WortnS. " "Worms?" "Intestinal worms. You'll never again pass a worm if you eat a fistful of dulse first thing in the morning and last thing at night. " "If it's an anthelmintic, I'll try a spot of it," said Potter. - From Bogmail, a novel by Patrick McGinley (1981) With modern techniques of chemical isolation and structure determination, the old distinction between herbal and chemical remedies has largely been broken down. By chemotherapy we now mean simply the treatment of disease by drugs (the word medicines has unhappily been eclipsed). The distinction made between chemotherapy and non chemical therapy (e. g. , radiation, physiotherapy, surgical intervention, immu nomodulation) remains useful despite some minor overlapping. The present work thus deals with drugs and their use in parasitic disease. (Since we are dealing with the treatment of incipient as well as established infection, chemotherapy subsumes chem oprophylaxis as well as chemotherapeusis per se. ) Definition of parasitism as a biological modus vivendi, although important in itself, need not concern us here. We need simply delimit the scope of the book, and that is easily done.

This major reference work is the most comprehensive resource on oncologic critical care. The text reviews all significant aspects of oncologic ICU practices, with a particular focus on challenges encountered in the diagnosis and management of the critically ill cancer patient population. Comprised of over 140 chapters, the text explores such topics as the organization and management of an oncologic ICU, diseases and complications encountered in the oncologic ICU, multidisciplinary care, surgical care, transfusion medicine, special patient populations, critical care procedures, ethics, pain management, and palliative care. Written by worldwide experts in the field, Oncologic Critical Care is a valuable resource for intensivists, advance practice providers, nurses, and other healthcare providers, that will help close significant knowledge and educational gaps within the realm of medical care for critically ill cancer patients.

One of the top four contributors to the global burden of disease is diarrheal infections. Intestinal parasites are major causes of morbidity and mortality associated with diarrheal diseases in both the developed and developing world. Amebiasis is responsible for 50 million cases of invasive disease and 70,000 deaths annually in the world. Giardiasis has an estimated worldwide prevalence of 280 million cases annually. In developed countries, Giardia lamblia infects about 2% of adults and 6-8% of children. The prevalence of G. lamblia infection is generally higher in developing countries, ranging from 3% to 90%. Furthermore, giardial infections contribute substantially to the 2.5 million annual deaths from diarrheal disease. In Asia, Africa, and Latin America, about 500,000 new giardiasis cases are reported each year. Cryptosporidium accounts for 20% and 9% of diarrheal episodes in children in developing and developed countries, respectively. Infection with Cryptosporidium can be chronic and especially debilitating in immunosuppressed individuals and malnourished children. A recent study to measure disease burden, based on disability-adjusted life years (DALYs), found that cryptosporidiosis and amebiasis produce about 10.6 million DALYs. This exceeds the DALYs of any helminth infection currently being targeted by the World Health Organization for preventive chemotherapy. Because of its link with poverty, Giardia and Cryptosporidium were included in the WHO Neglected Diseases Initiative in 2004. E. histolytica, G. lamblia, and C. parvum have been listed by the National Institutes of Health (NIH) as category B priority biodefense pathogens due to low infectious dose and potential for dissemination through compromised food and water supplies in the United States. Despite the prevalence of amebiasis, giardiasis, and cryptosporidiosis there are no vaccines or prophylactic drugs. The first-line drugs for invasive amebiasis and giardiasis chemotherapy are nitroimidazoles, with the prototype, metronidazole, being the most common drug used worldwide. Metronidazole has been shown to be both mutagenic in a microbiological system and carcinogenic to rodents, and frequently causes gastrointestinal side effects. In spite of the efficacy of nitroimidazole drugs, treatment failures in giardiasis occur in up to 20% of cases. Clinical resistance of G. lamblia to metronidazole is proven and cross resistance is a concern with all commonly used antigiardial drugs. Nitazoxanide, the only FDA-approved drug for the treatment of cryptosporidiosis, is effective in the treatment of immunocompetent patients and partially effective for immunosuppressed patients. Therefore, it is critical to search for more effective drugs to treat amebiasis, giardiasis, and cryptosporidiosis. This Research Topic for Frontiers in Microbiology will explore the recent progress in drug development for parasitic diarrheal diseases. This includes an understanding of drug resistance mechanisms. We would also welcome submissions on the drug development for other diarrheal parasites. We hope that this research topic will include a comprehensive survey of various attempts by the parasitology research community to create effective drugs for these diseases.

With the knowledge that there are several pieces of information concerning the chemotherapy of trypanosomatids, it is important to put together the different aspects of this subject. This book is an updated version of several areas such as molecular biology, biochemistry, immune response to the studied compounds, pharmacology, etc. The chapters were written by experts in those different specialties. It reinforces the necessity to look to those trypanosomatids associated with severe diseases, such as Chagas disease, leishmaniases and African trypanosomiasis, which constitute a public health problem in poor countries where basic sanitary conditions are non-existent. This book intends to show the importance of specific methodologies to save time and money during the drug development process. Each step should be carefully planned from the selection of test compounds, the choice of a molecular target within parasites, the definition of a lead compound and the adequacy of the animal models. It is also important to focus on the activity of compounds, synthetic or from natural sources, in different species and life stages of the parasites, besides the way these compounds are metabolized in these laboratory conditions. In conclusion, this book will bring you information that could stimulate the development of better treatments for these highly neglected diseases.